FDA Approves MOXIFLOXACIN — Macleods Pharmaceuticals Limited
# FDA Approves Generic Moxifloxacin ANDA from Macleods Pharmaceuticals Macleods Pharmaceuticals Limited has received FDA approval for its generic moxifloxacin hydrochloride oral formulation (ANDA209143), expanding competitive options in the fluoroquinolone antibiotic market and potentially putting downward pricing pressure on the branded Avelox product. The approval strengthens Macleods' portfolio in the U.S. market and allows the company to capture market share in a therapeutic category used to treat bacterial infections across multiple patient populations
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day